RNXT 1.00 RenovoRx, Inc.
| Range: | 0.531-2.35 | Vol Avg: | 31962 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 0.98 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Aug 26 2021 | Empoloyees: | 8 | ||
| CUSIP: | 75989R107 | CIK: | 0001574094 | ISIN: | US75989R1077 | Country: | US |
| CEO: | Mr. Shaun R. Bagai | Website: | https://renovorx.com | ||||
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow